Vaxcyte Inc (PCVX) Stock Price, Quote & News

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 0111

Website: vaxcyte.com

Address:

825 Industrial Road, Suite 300, San Carlos, United States

NorthStarStats Apr. 1 at 1:45 AM

Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $CSX Score 100, $NUVL Score 100, $AZN Score 100, $WAB Score 100, $PCVX Score 98

0 · Reply

greensmell Mar. 7 at 4:42 AM

$PCVX $MRNA https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3?mod=e2tw

0 · Reply

KY3000 Mar. 7 at 12:02 AM

$PCVX HMPV, no vaccine can treat it, this should be their next target

0 · Reply

BillionerOfKing Mar. 3 at 2:34 AM

$PCVX Current Stock Price: $61.97 Contracts to trade: $60.0 PCVX Mar 20 2026 Call Entry: $3.90 Exit: $7.48 ROI: 92% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

KY3000 Feb. 28 at 7:14 PM

$PCVX don’t worry about production

0 · Reply

erevnon Feb. 26 at 11:54 AM

BTIG maintains Vaxcyte $PCVX at Buy and raises the price target from $85 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

KY3000 Feb. 25 at 10:34 PM

$PCVX needs to announce another target, they going to be commercialized sooner than later

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:16 AM

$PCVX RSI: 63.50, MACD: 1.9469 Vol: 1.77, MA20: 54.85, MA50: 49.71 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SuperGreenToday Feb. 9 at 7:17 PM

$PCVX Share Price: $55.51 Contract Selected: Jul 17, 2026 $55 Calls Buy Zone: $6.54 – $8.09 Target Zone: $11.59 – $14.16 Potential Upside: 67% ROI Time to Expiration: 157 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

OfficialStocktwitsUser Feb. 5 at 5:19 AM

$PCVX RSI: 64.71, MACD: 2.4385 Vol: 3.94, MA20: 50.53, MA50: 47.97 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Mar 18, 2026, 7:34 PM EDT - 17 days ago

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Feb 24, 2026, 11:27 PM EST - 5 weeks ago

Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript

Feb 24, 2026, 4:05 PM EST - 5 weeks ago

Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Feb 11, 2026, 4:05 PM EST - 7 weeks ago

Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines

Feb 10, 2026, 4:05 PM EST - 7 weeks ago

Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026

Feb 5, 2026, 4:05 PM EST - 2 months ago

Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit

Feb 2, 2026, 4:05 PM EST - 2 months ago

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 29, 2026, 11:33 PM EST - 2 months ago

Vaxcyte Announces Pricing of $550 Million Public Offering

Jan 29, 2026, 10:30 PM EST - 2 months ago

Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance

ABBV ABVX CVLT FIX FTAI GKOS GMAB

Jan 29, 2026, 4:06 PM EST - 2 months ago

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 22, 2026, 5:00 PM EST - 2 months ago

Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine

Dec 22, 2025, 8:19 AM EST - 3 months ago

This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.

Dec 16, 2025, 9:26 AM EST - 3 months ago

Vaxcyte: Financial Durability And The Case For Disruption

Dec 8, 2025, 7:00 AM EST - 4 months ago

Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

Nov 4, 2025, 4:05 PM EST - 5 months ago

Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study

Sep 30, 2025, 8:30 AM EDT - 6 months ago

Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

Sep 7, 2025, 10:01 PM EDT - 7 months ago

Vaxcyte, Inc. (PCVX) Presents At Cantor Global Healthcare Conference 2025 Transcript

Sep 3, 2025, 7:30 AM EDT - 7 months ago

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

Aug 6, 2025, 4:05 PM EDT - 8 months ago

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

May 7, 2025, 4:01 PM EDT - 11 months ago

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 1 year ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Mar 31, 2025, 6:21 PM EDT - 1 year ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI

Mar 31, 2025, 3:39 PM EDT - 1 year ago

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Mar 31, 2025, 8:56 AM EDT - 1 year ago

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Mar 31, 2025, 7:00 AM EDT - 1 year ago

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Mar 30, 2025, 5:00 PM EDT - 1 year ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Feb 26, 2025, 3:26 AM EST - 1 year ago

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:01 PM EST - 1 year ago

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 12, 2025, 4:05 PM EST - 1 year ago

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Feb 5, 2025, 8:00 AM EST - 1 year ago

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Jan 30, 2025, 4:05 PM EST - 1 year ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 11:51 AM EST - 1 year ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Jan 15, 2025, 7:15 AM EST - 1 year ago

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

PFE

Dec 3, 2024, 8:00 AM EST - 1 year ago

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Nov 12, 2024, 7:30 AM EST - 1 year ago

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Nov 5, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Sep 8, 2024, 9:00 AM EDT - 1 year ago

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Sep 6, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 6, 2024, 3:07 PM EDT - 1 year ago

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Sep 6, 2024, 9:07 AM EDT - 1 year ago

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Sep 5, 2024, 1:22 AM EDT - 1 year ago

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Sep 4, 2024, 11:58 PM EDT - 1 year ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 3, 2024, 10:48 AM EDT - 1 year ago

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Sep 3, 2024, 10:10 AM EDT - 1 year ago

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Sep 3, 2024, 9:24 AM EDT - 1 year ago

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Sep 3, 2024, 8:51 AM EDT - 1 year ago

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Sep 3, 2024, 7:07 AM EDT - 1 year ago

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 2, 2024, 6:40 PM EDT - 1 year ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

NorthStarStats Apr. 1 at 1:45 AM

0 · Reply

greensmell Mar. 7 at 4:42 AM

$PCVX $MRNA https://www.wsj.com/health/healthcare/fdas-controversial-vaccines-chief-will-leave-the-agency-7fe59aa3?mod=e2tw

0 · Reply

KY3000 Mar. 7 at 12:02 AM

$PCVX HMPV, no vaccine can treat it, this should be their next target

0 · Reply

BillionerOfKing Mar. 3 at 2:34 AM

0 · Reply

KY3000 Feb. 28 at 7:14 PM

$PCVX don’t worry about production

0 · Reply

erevnon Feb. 26 at 11:54 AM

BTIG maintains Vaxcyte $PCVX at Buy and raises the price target from $85 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

KY3000 Feb. 25 at 10:34 PM

$PCVX needs to announce another target, they going to be commercialized sooner than later

0 · Reply

OfficialStocktwitsUser Feb. 21 at 10:16 AM

0 · Reply

SuperGreenToday Feb. 9 at 7:17 PM

0 · Reply

OfficialStocktwitsUser Feb. 5 at 5:19 AM

0 · Reply

BuffettStyleInvestments Feb. 4 at 11:54 AM

$PCVX is a vaccine developer with a promising pneumococcal candidate; its valuation is binary on phase 3 data and potential market disruption of entrenched players.

0 · Reply

CC01 Jan. 30 at 6:10 PM

$PCVX Strong buy

0 · Reply

KY3000 Jan. 23 at 3:17 PM

$STRO if you believe in $PCVX, than 300$ mill in milestones is a lock

0 · Reply

Night_Owl_Biotech Jan. 23 at 2:15 AM

The XBI is up 6% over the last 3 trading sessions. The XBI held 145 bio focused stocks as of Tuesday 1/20/2026. Attached is a schedule of the largest gains (by dollar) & all stocks down over the last 3 days. 124 of the 145 or 86% of these bio stocks have traded higher. 1 is unchanged & only 20 are down. $MRNA & $CRVS have produced the largest dollar gains for the XBI over the last 3 days. $PRAX is off the most by $ value (though is up 500% since reporting the data from their movement disorder therapy). PRAX has raised over $1B over the last 3 months. We believe $PCVX will eventually be acquired by $PFE

0 · Reply

theCATALYST Jan. 22 at 9:13 PM

$ARVN $PCVX $SLDB +89% / +66% / +123%

0 · Reply

samiztech2022 Jan. 21 at 7:02 PM

$PCVX on the move, next $JELD , NFA

0 · Reply

Ariad Jan. 21 at 6:00 PM

$PCVX Analyst say big upside on this vaccine name. And Nice chart and good price action during volatility. $TSLA $RUN

0 · Reply

Hognose Jan. 14 at 7:06 PM

$VKTX $ASND $RYTM $ABVX $PCVX my potential buyout portfolio.

0 · Reply

anachartanalyst Jan. 7 at 12:01 PM

$PCVX https://anachart.com/wp-content/uploads/ana_temp/1767787274_soc-img.jpg

0 · Reply

infiniteM Dec. 13 at 8:21 AM

$PCVX tokd you....

0 · Reply

BillionerOfKing Dec. 5 at 6:59 PM

$PCVX Current Stock Price: $45.82 Contracts to trade: $45 PCVX Dec 19 2025 Call Entry: $0.40 Exit: $0.77 ROI: 93% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Market Cap	8.40B
Revenue (ttm)	0.00
Net Income (ttm)	-766.63M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,017,800
Avg Vol	1,513,796
Day's Range	N/A - N/A
Shares Out	143.92M
Stochastic %K	81%
Beta	1.38
Analysts	Strong Sell
Price Target	$109.00